Medolev® (Carbidopa + Levodopa)

12 Oct 2020
                                                        





VIEW PRODUCT INFORMATION
[link to https://mims.com/philippines/drug/info/medolev%20125-medolev%20275]


Carbidopa + Levodopa (Medolev®) – Levodopa, precursor of dopamine, used as dopamine replacement agent for PD.1–3 It is also used to manage bradykinetic symptoms in PD and improve the quality of life of patients with idiopathic PD.3 Carbidopa, an analogue of levodopa, inhibits dopa decarboxylase (enzyme present in the central and peripheral tissue). It reduces adverse effects such as nausea and vomiting.4 Levodopa is usually combined with carbidopa to enhance bioavailability and diminish fluctuations in the plasma level.5 The combination of carbidopa and levodopa remains as the most effective drug in improving the symptoms and quality of life of patients with PD.6

References:
1. Khor SP, et al. Curr Clin Pharmacol 2007;2:234–43.
2. Brüssow H. Environ Microbiol 2020;22:808–812.
3. Gandhi KR, Saadabadi A. Levodopa (L-Dopa). National Center for Biotechnology Information resource page. Available at: https://www.ncbi.nlm.nih.gov/books/NBK482140/. Accessed 15 June 2020.
4. Busti AJ. Why is carbidopa added to levodopa (ie L-dopa, Sinemet, Sinemet CR). Evidence-based Medicine Consult resource page. Available at: https://www.ebmconsult.com/articles/carbidopa-levodopa-parkinson-disease. Accessed 10 June 2020.
5. Tambasco N, et al. Curr Neuropharmacol 2018;16:1239–1252. 6. Münchau A, Bhatia KP. Postgrad Med J 2000;76:602–610.



MULTICARE PHARMACEUTICALS PHILIPPINES, INC.
28th Floor, Rufino Tower, 6784 Ayala Avenue, Makati City
Tel. No. (632)8811-0636 | www.multicare.com.ph